SIGMA ADVANCED SYSTEMS LIMITED — Capital/Financing Update 2025

Jul 1, 2025

==> picture [452 x 101] intentionally omitted <==

To,

Date: July 1, 2025

BSE Limited Phiroze JeeJee Bhoy Towers Dalal Street, Fort Mumbai 400001 Scrip Code:532408	National Stock Exchange of India Limited Exchange Plaza Bandra-Kurla Complex, Bandra(E) Mumbai 400051 Symbol:MEGASOFT

Sub.: Outcome of the Board Meeting held on July 1, 2025

Ref: Disclosure pursuant to Regulation 30 of Securities and Exchanges Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

This intimation is pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015 regarding sale/ transfer or otherwise disposal of the whole or substantially the whole of an undertaking of the Company viz., Sale of Investment of Megasoft Limited’s holding of 36.52% in Extrovis AG, Switzerland.

Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the said Regulations, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 and Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 11[th] and 13[th] July, 2023, respectively are enclosed herewith as Annexure I.

We further wish to inform that the Meeting of the Board of Directors of the company commenced at 7:15 p.m. and concluded at 8:00 p.m.

You are requested to kindly take the above information on record.

Thanking you,

Yours faithfully,

For Megasoft Limited

THAKUR Digitally signed by THAKUR VISHAL VISHAL SINGH Date: 2025.07.01 SINGH 20:03:06 +05'30'

……………………………….

Thakur Vishal Singh

Company Secretary & Compliance Officer

==> picture [452 x 13] intentionally omitted <==

==> picture [452 x 101] intentionally omitted <==

Annexure I

		Annexure I
S. No.	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	The undertaking being an associate company, it’s financials does not have any impact on the standalone financials of the listed entity. Only the loss of the undertaking has been taken, on a proportionate basis, into the listed entity financials at the consolidatedlevel.
2.	Date of Sale Agreement / Share Purchase Agreement (SPA)	The Sale Agreement / Share Purchase Agreement (SPA) is yet to be executed.
3.	The expected date of completion of sale/disposal	The Sale Agreement / Share Purchase Agreement (SPA) is yet to be executed.
4.	Consideration expected to be received from such sale/ disposal	US $ 15,000,000 (in one or more tranches) and subject to terms of definitive agreement(s) as may be executed between the company and the buyer. Approximately INR 128.40 Crores subject to foreign exchange fluctuations.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Name of the Buyer: Refex Life Sciences Private Limited The buyers do not belong to the promoter/ promoter group/group companies.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at“arm’s length”;	No.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Yes, the sale of above-mentioned undertaking is outside the scheme of arrangement. The company will seek approval of the shareholders through a postal ballot in due course.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

==> picture [452 x 13] intentionally omitted <==